Abstract
Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.
Keywords: 18F-FDG, positron emission tomography, SPECT, imaging, radiopharmaceutical, 9mTc, 188Re
Current Pharmaceutical Design
Title: Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Volume: 15 Issue: 9
Author(s): Y. Y. Sun and Y. Chen
Affiliation:
Keywords: 18F-FDG, positron emission tomography, SPECT, imaging, radiopharmaceutical, 9mTc, 188Re
Abstract: Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.
Export Options
About this article
Cite this article as:
Sun Y. Y. and Chen Y., Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582048
DOI https://dx.doi.org/10.2174/138161209787582048 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Current Molecular Pharmacology U1 snRNP Control of 3´-End Processing and the Therapeutic Application of U1 Inhibition Combined with RNA Interference
Current Molecular Medicine Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Bone Regeneration: Microparticulate and Biomimetic Strategies
Current Tissue Engineering (Discontinued) Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Exploring the Bio-efficacies of Methanolic Extracts of Nostoc muscorum and Calothrix brevissima with their Characterization Using GC-MS
The Natural Products Journal New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Trypsin-Chymotrypsin Inhibitors from Vigna mungo Seeds
Protein & Peptide Letters Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Pathobiology of Head and Neck Squamous Tumorigenesis
Current Cancer Drug Targets Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design